NCT00773812View on ClinicalTrials.gov

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Autistic DisorderPervasive Developmental Disorder
Interventions
DRUG

mecamylamine

The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.

DRUG

placebo

One pill is taken once daily.

Trial Locations (1)

43210

Nisonger Center, Columbus

All Listed Sponsors
collaborator

Autism Speaks

OTHER

lead

Ohio State University

OTHER

NCT00773812 - Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter